Home
/ Sundia
/ Competitors

Sundia Competitors and Similar CompaniesClear all

Sundia's competitors and similar companies include Novartis, Pfizer, Tara Innovations and CMIC Holdings.

	Sundia Sundia MediTech is a preclinical contract research organization providing drug discovery and development services.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Tara Innovations Tara Innovations is a pharmaceutical contract research organization (CRO), focused on drug development.	CMIC Holdings CMIC Holdings (シミックホールディングス株式会社, also known as CMIC Group) is a contract research organization that focuses on the pharmaceutical industry.
Founding Date	Founding Date 2004	Founding Date 1996	Founding Date 1849	Founding Date 2008	Founding Date 1985
Type	Type Private	Type Public	Type Public	Type Private	Type Subsidiary
Tags	Tags Healthcare biotech clinical research contractor drug development pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare clinical research contractor drug development pharma	Tags Healthcare clinical research data management drug development pharma
Locations	Locations HQ Shijiazhuang Shi, CN Sacramento, US	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more	Locations Parsippany-Troy Hills, US HQ East Hanover, US	Locations Tokyo, JP HQ Brisbane, AU Beijing, CN Hong Kong, HK Fukuoka, JP Hachimantai, JP Hokuto, JP see more
Employees	Employees 120	Employees 75,883	Employees 81,0008% decrease	Employees 5	Employees 4,684
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) $62.6b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)	Cost of goods $16.1b (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $49.8b (FY, 2025)	Gross profit $46.5b (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income $14b (FY, 2025)	Net income $7.8b (FY, 2025)	Net income N/A	Net income N/A
Operating ⚠
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 44 (FY, 2022)	Phase III Trials Products 32 (FY, 2024)	Phase III Trials Products N/A	Phase III Trials Products N/A
Registration Phase Products	Registration Phase Products N/A	Registration Phase Products 8 (FY, 2022)	Registration Phase Products 5 (FY, 2024)	Registration Phase Products N/A	Registration Phase Products N/A
Funding
Total funding raised	Total funding raised $ 10.5m	Total funding raised $ 6.5m	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A